PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
You may also be interested in...
US FDA Planning Another Patient Group To Boost Involvement
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.
Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.
Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.